UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): JULY 22, 2003
THE MEDICINES COMPANY
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-31191 04-3324394
---------------------------- -------------- ----------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
8 CAMPUS DRIVE
PARSIPPANY, NEW JERSEY 07054
---------------------------------------- -----------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 656-1616
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 9. REGULATION FD DISCLOSURE (INFORMATION FURNISHED PURSUANT TO ITEM 12,
"DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").
On July 22, 2003, The Medicines Company (the "Company") announced its
financial results for the quarter and six month period ended June 30, 2003. The
full text of the press release issued in connection with the announcement is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with the procedural guidance in SEC Release No. 33-8216, the
information in this Current Report on Form 8-K, including Exhibit 99.1, is being
furnished under "Item 9. Regulation FD Disclosure" rather than under "Item 12.
Disclosure of Results of Operations and Financial Condition." In accordance with
General Instruction B.6 of Form 8-K, the information shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE MEDICINES COMPANY
Date: July 22, 2003 By: /s/ Steven H. Koehler
--------------------------
Steven H. Koehler
Vice President and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated July 22, 2003 entitled "The
Medicines Company Reports Second Quarter 2003 and
Mid-Year Financial Results."